By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Choriogonadotropin alfa (monograph)
Drugs

Choriogonadotropin alfa (monograph)

https://themeditary.com/drug/choriogonadotropin-alfa-monograph-7923.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Aug 16, 2023  Additional Content by TheMediTary.Com

Generic name: ovidrel

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Novarel (injectable), Ovidrel (injectable), Pregnyl (injectable), Human chorionic gonadotropin (hcg), Human chorionic gonadotropin

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Choriogonadotropin alfa (monograph)?

Introduction

Gonad-stimulating hormone; biosynthetic (recombinant DNA-derived) form of human chorionic gonadotropin (hCG).

Uses for Choriogonadotropin Alfa

Female Infertility

Used in conjunction with other infertility agents (e.g., gonadotropin-releasing hormone agonist, FSH) for induction of final follicular maturation and early luteinization in ovulatory, infertile women during assisted reproductive technology (ART) programs.

Use in patients with tubal obstruction only if participating in ART programs.

Choriogonadotropin alfa (r-hCG) is equivalent to urinary-derived hCG with regard to number of oocytes recovered, fertilized oocytes or embryos, and live births.

Used in conjunction with follicle-stimulating agent to induce ovulation in anovulatory, infertile women in whom anovulation is functional and not due to primary ovarian failure.

Choriogonadotropin alfa (r-hCG) is similar to urinary-derived hCG with regard to ovulation rates.

Choriogonadotropin Alfa Dosage and Administration

General

  • Should be prescribed only by clinicians experienced in infertility treatment and who are familiar with cautions, precautions, and contraindications associated with such therapy.

  • Prior to treatment initiation with choriogonadotropin alfa, perform a thorough gynecologic and endocrinologic evaluation; assess pelvic anatomy and rule out early pregnancy, primary ovarian failure (as indicated by increased serum concentrations of FSH and LH and low serum estrogen concentrations), and neoplasms. (See Contraindications under Cautions.) Perform a thorough diagnostic evaluation in patients who demonstrate abnormal uterine bleeding and other signs of endometrial abnormalities. (See Contraindications under Cautions.) Evaluate partner’s infertility.

  • When ultrasound assessment and serum estradiol concentrations show sufficient follicular maturation, administer choriogonadotropin alfa 1 day after last dose of follicle-stimulating agent to complete final follicular maturation and induce ovulation.

  • Withhold further follicle-stimulating therapy and delay or withhold choriogonadotropin alfa if ovaries show an excessive response to treatment with gonadotropins because of increased risk of ovarian hyperstimulation syndrome (OHSS). (See Ovarian Hyperstimulation Syndrome under Cautions.)

  • Encourage daily sexual intercourse beginning 1 day prior to administration of choriogonadotropin alfa until ovulation occurs (as determined by rise in basal body temperature, increase in serum progesterone concentrations, and menstruation following shift in basal body temperature). (See Adequate Patient Evaluation and Monitoring under Cautions.)

  • Examine ovaries by ultrasound for persistent cysts, particularly when attempts at stimulation of ovulation follow immediately after unsuccessful stimulated cycle.

Administration

Sub-Q Administration

Administer by sub-Q injection, generally into abdomen using commercially available prefilled syringe; may be self-administered by patient.

Dosage

Adults

Female Infertility
ART
Sub-Q

250 mcg, given 1 day following last dose of follicle-stimulating agent. (See General under Dosage and Administration.)

Ovulation Induction
Sub-Q

250 mcg, given 1 day following last dose of follicle-stimulating agent. (See General under Dosage and Administration.)

If stimulation of ovulation is unsuccessful, adjust dosage of follicle-stimulating agent administered in subsequent cycles based on woman’s response in preceding cycle.

Prescribing Limits

Adults

Female Infertility
Sub-Q

Maximum 500-mcg single dose studied in clinical trials.

Detailed Chorionic gonadotropin (hcg) dosage information

Warnings

Contraindications

  • Known hypersensitivity to human chorionic gonadotropin preparations (including urinary-derived hCG) or any ingredient in formulation.

  • Primary ovarian failure.

  • Uncontrolled thyroid or adrenal dysfunction.

  • Uncontrolled organic intracranial lesions (e.g., pituitary neoplasms).

  • Abnormal intrauterine or vaginal bleeding of undetermined origin.

  • Ovarian cysts or enlargement of undetermined origin.

  • Sex-hormone-dependent neoplasms of reproductive tract and accessory organs.

  • Pregnancy.

Warnings/Precautions

Warnings

Ovarian Enlargement

Risk of mild to moderate uncomplicated ovarian enlargement; may be accompanied by abdominal distention and/or pain, but generally regresses without treatment within 2–3 weeks. Careful monitoring of ovarian response recommended.

If ovaries are abnormally enlarged during controlled ovarian stimulation, withhold choriogonadotropin alfa during current course of therapy to minimize risk of OHSS. (See Ovarian Hyperstimulation Syndrome under Cautions.)

Ovarian Hyperstimulation Syndrome

Risk of potentially severe OHSS, characterized by apparent dramatic increase in vascular permeability that may result in rapid accumulation of fluid in peritoneal cavity, thorax, and potentially, pericardium.

May progress rapidly (within 24 hours to several days). Initial manifestations include severe pelvic pain, nausea, vomiting, and weight gain. Other symptoms include abdominal pain/distention, diarrhea, severe ovarian enlargement, dyspnea, and oliguria. Hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic events may occur.

Transient liver function test abnormalities, which may be accompanied by morphologic changes (as detected by liver biopsy), reported.

Occurs most often after completion of gonadotropin therapy, reaching maximum severity after 7–10 days; usually resolves spontaneously with onset of menses. Monitor patients for ≥2 weeks after hCG administration. OHSS may be more severe and protracted if pregnancy occurs.

If severe OHSS develops, discontinue therapy, hospitalize patient, and consult clinician experienced in management of OHSS or fluid and electrolyte imbalances.

Multiple Births

Multiple ovulations resulting in multiple gestations reported in 30.9 or 13.3% of women during ART programs or ovulation induction, respectively.

Risk of multiple births correlates with number of embryos transferred.

Thromboembolism

Potential for arterial thromboembolism exists.

Fetal/Neonatal Morbidity and Mortality

May cause fetal harm; exclude pregnancy before initiating treatment.

Animal studies indicate adverse effects on pregnancy outcomes and/or labor. (See Contraindications under Cautions.)

General Precautions

Adequate Patient Evaluation and Monitoring

Administer only under supervision of qualified clinicians experienced in fertility disorders and interpretation of indices of ovulation.

Monitor follicular development (e.g., using transvaginal ultrasound, serum estradiol concentrations) to correctly identify follicular maturation, determine timing of choriogonadotropin alfa administration, detect ovarian enlargement, and minimize risks of OHSS and multiple gestation.

Obtain clinical confirmation of ovulation from direct and indirect indices of progesterone production, including rise in basal body temperature, an increase in serum progesterone concentrations, and menstruation following shift in basal body temperature. Sonographic evidence of ovulation includes findings of fluid in cul-de-sac, ovarian stigmata, collapsed follicle, and secretory endometrium.

Specific Populations

Pregnancy

Category X. (See Fetal/Neonatal Morbidity and Mortality and also Contraindications under Cautions.)

Lactation

Not known whether choriogonadotropin alfa is distributed into milk. Use caution.

Pediatric Use

Safety and efficacy not established.

Geriatric Use

Safety and efficacy not established.

Hepatic Impairment

Safety and efficacy not established.

Renal Impairment

Safety and efficacy not established.

Common Adverse Effects

ART: Injection site reactions (i.e., pain, bruising), abdominal pain, nausea, vomiting, postoperative pain.

Ovulation induction: Injection site reactions (i.e., pain, inflammation, bruising, other injection site reaction), ovarian cysts, ovarian hyperstimulation, abdominal pain.

How should I use Choriogonadotropin alfa (monograph)

General

  • Should be prescribed only by clinicians experienced in infertility treatment and who are familiar with cautions, precautions, and contraindications associated with such therapy.

  • Prior to treatment initiation with choriogonadotropin alfa, perform a thorough gynecologic and endocrinologic evaluation; assess pelvic anatomy and rule out early pregnancy, primary ovarian failure (as indicated by increased serum concentrations of FSH and LH and low serum estrogen concentrations), and neoplasms. (See Contraindications under Cautions.) Perform a thorough diagnostic evaluation in patients who demonstrate abnormal uterine bleeding and other signs of endometrial abnormalities. (See Contraindications under Cautions.) Evaluate partner’s infertility.

  • When ultrasound assessment and serum estradiol concentrations show sufficient follicular maturation, administer choriogonadotropin alfa 1 day after last dose of follicle-stimulating agent to complete final follicular maturation and induce ovulation.

  • Withhold further follicle-stimulating therapy and delay or withhold choriogonadotropin alfa if ovaries show an excessive response to treatment with gonadotropins because of increased risk of ovarian hyperstimulation syndrome (OHSS). (See Ovarian Hyperstimulation Syndrome under Cautions.)

  • Encourage daily sexual intercourse beginning 1 day prior to administration of choriogonadotropin alfa until ovulation occurs (as determined by rise in basal body temperature, increase in serum progesterone concentrations, and menstruation following shift in basal body temperature). (See Adequate Patient Evaluation and Monitoring under Cautions.)

  • Examine ovaries by ultrasound for persistent cysts, particularly when attempts at stimulation of ovulation follow immediately after unsuccessful stimulated cycle.

Administration

Sub-Q Administration

Administer by sub-Q injection, generally into abdomen using commercially available prefilled syringe; may be self-administered by patient.

Dosage

Adults

Female Infertility
ART
Sub-Q

250 mcg, given 1 day following last dose of follicle-stimulating agent. (See General under Dosage and Administration.)

Ovulation Induction
Sub-Q

250 mcg, given 1 day following last dose of follicle-stimulating agent. (See General under Dosage and Administration.)

If stimulation of ovulation is unsuccessful, adjust dosage of follicle-stimulating agent administered in subsequent cycles based on woman’s response in preceding cycle.

Prescribing Limits

Adults

Female Infertility
Sub-Q

Maximum 500-mcg single dose studied in clinical trials.

Detailed Chorionic gonadotropin (hcg) dosage information
Choriogonadotropin alfa (monograph) Dosage information (more detail)

What other drugs will affect Choriogonadotropin alfa (monograph)?

No formal drug interaction studies to date.

Laboratory Tests

Test

Interaction

Comments

Radioimmunoassays for gonadotropins

Possible cross-reaction with radioimmunoassays for gonadotropins, particularly LH

Individual laboratories should establish degree of cross-reactivity with their gonadotropin assay

When requesting gonadotropin concentration determinations, inform laboratory of choriogonadotropin alfa therapy

More about Choriogonadotropin alfa (monograph) (Ovidrel)

Dosage information
Choriogonadotropin alfa (monograph) Side Effects
During pregnancy
Drug images
Side effects
Drug class: Drugs

Related treatment guides

Weight Loss (Obesity/Overweight)
Hypogonadism, Male
Prepubertal Cryptorchidism
Ovulation Induction
Metabolic Disorders
Female Infertility
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by